Why I think this FTSE 250 stock looks overvalued and ready to slump

This FTSE 250 (INDEXFTSE:MCX) company could be a disappointment for its investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

While it is important for a company to deliver improved financial performance, there is much more to investing than picking stocks with growing profitability. In fact, in many cases a company’s future prospects may be priced-in to its valuation. Therefore, new investors may not enjoy significant upside over the medium term. Reporting on Thursday was a company which appears to neatly fit into that category.

Improving performance

The company in question is industrial engineering specialist Spirax-Sarco (LSE: SPX). Its financial performance in 2016 represented a significant step up from its 2015 numbers. For example, revenue increased by 14% and adjusted operating profit was 18% higher. The latter benefitted from an increased operating margin, with it rising by 100 basis points. This allowed the company to increase dividends by 10% and with cash conversion of 101%, 2016 was an excellent year for the business.

This came at a time when the company’s operating conditions were challenging. Global industrial production was low in 2016, and Spirax-Sarco was generally able to outperform its markets. Its investment in improving margins and delivering robust organic growth of 4% proved to be a sensible strategy to pursue. As such, it seems to be well-positioned to deliver higher growth in future years.

Investment potential

In 2017, Spirax-Sarco is expected to record a rise in earnings of 10%, followed by further growth of 6% next year. While this rate of growth is slightly higher than the expected growth rate of the wider index, it does not indicate a particularly strong performance lies ahead for the company.

Despite this, its shares trade on a premium valuation. They have a price-to-earnings (P/E) ratio of 26.8, which is in excess of their four-year average P/E ratio of 21.6. Therefore, there seems to be scope for a major derating of Spirax-Sarco’s shares over the medium term. If their P/E ratio reverts to the long-term average then a share price fall in the high single-digits could be on the cards. That’s assuming the company is able to continue to outperform the wider global industrial production sector, which is not guaranteed.

Higher growth potential

Within the same industry as Spirax-Sarco is specialist engineering company IMI (LSE: IMI). It is forecast to record a rise in earnings of just 1% this year, but is due to follow that up with growth of 12% next year. As well as offering superior growth potential than its sector peer, IMI trades on a lower valuation. It has a P/E ratio of 20.2. When combined with its forecast growth rate, this equates to a price-to-earnings growth (PEG) ratio of just 1.7. This compares to a PEG ratio of around 3.3 for its sector peer.

Clearly, the industrial sector is an uncertain industry in which to invest at the present time. Both Spirax-Sarco and IMI seem to be performing better than their wider industries, which is encouraging for their investors. However, since the latter offers a significantly lower valuation than the former, it seems to be the only one of the two companies worthy of investment at the present time.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended IMI. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »